Our results confirm the role of PKCε as an oncogene in RCC, especially in the subtype of clear cell, suggesting that PKCε might be a potential treatment target for this disease, which warrants verification in further studies. This evidence concerns the gene PRKCE and renal cell adenocarcinoma.